科研团队

李开龙副研究员课题组
1. 个人简介:
李开龙,生物化学与分子生物学系副研究员,博士生导师。2015年获得北京协和医学院(清华大学医学部)病理与病理生理学博士学位,2015年至2021年于美国德克萨斯大学西南医学中心Jian Xu实验室从事博士后研究,致力于生理及病理状态下增强子的结构及功能解析。2021年6月入职北京大学基础医学院,开展遗传调控、表观遗传调控及相关疾病的研究。近5年来研究成果以第一/共同第一作者身份发表于Cancer Discovery,Nature Communications及Signal Transduction and Targeted Therapy等学术杂志上,其他几项合作工作发表于Cell,Nature等学术杂志上。曾荣获CPRIT Training Grant (2018, 2019), the Travel Award for Best Postdoc Poster, Cancer Biology Retreat (2019) 和the Collaborator of the Year Award, CRI(2020)等奖项。详见实验室网站:https://www.x-mol.com/groups/kailong_li_lab
2. 研究方向与领域:
基因表达调控的研究具有广泛的生物学意义。随着基因组学的广泛开展,基因的表达调控研究已经逐渐从单个基因点、线式的调控拓展到立体层面上多个基因、多个调控元件以至整个三维基因组的调控网络,其调控紊乱往往与疾病的发生发展密切相关。我们将致力于开发和运用基因编辑、功能基因组学、生物信息学等方法研究遗传调控和表观遗传调控紊乱在机体发育、肿瘤及其他遗传疾病发生发展中的作用。主要包括:
(1)非编码区调控序列变异在肿瘤发生发展及转移中的作用
(2)染色质三维结构变化在机体发育及肿瘤发生发展中的作用机制
(3) 表观基因组编辑系统在罕见遗传疾病精准治疗中的应用研究
3. 主要代表作:
(#Co-first author; *Co-corresponding author)
(1 )Shi L#, Li S#, Zhu R#, Lu C#, Xu X, Li C, Huang X, Zhao X*, Mao F*, Li K*. CRISPRepi: a multi-omic atlas for CRISPR-based epigenome editing. Nucleic Acids Res. 2025 Jan 6;53(D1):D901-D913.
(2 )Yang Y#, Wen D#, Lin F#, Song X, Pang R, Sun W, Yu D, Zhang Z, Yu T, Kong J, Zhang L, Cao X, Liao W, Wang D, Yang Q, Liang J, Zhang N, Li K*, Xiong C*, Liu Y*. Suppression of non-muscle myosin II boosts T cell cytotoxicity against tumor. Sci Adv. 2024 Nov;10(44):eadp0631.
(3 )Li K*, Wei G*, Yin Y*, Feng J*. Targeting Noncoding Cis-regulatory Elements for Cancer Therapy in Context of 3D Genome. Cancer Discov. 2024 Nov 1;14(11):2061-2065.
(4 )Zhang T#, Qiu L#, Cao J#, Li Q#, Zhang L#, An G, Ni J, Jia H, Li S*, Li K*. ZFP36 loss-mediated BARX1 stabilization promotes malignant phenotypes by transactivating master oncogenes in NSCLC. Cell Death Dis. 2023 Aug 16;14(8):527.
(5 )Cao F#, Jiang Y#, Chang L, Du H, Chang D, Pan C, Huang X, Yu D, Zhang M, Fan Y, Bian X*, Li K*. High-throughput functional screen identifies YWHAZ as a key regulator of pancreatic cancer metastasis. Cell Death Dis. 2023 Jul 14;14(7):431.
(6 )Chang D, Du H, Chen X, Bian X, Tian W, Shen J, Wei Y, Jiang Y, Dela Cruz C, Xie L*, Sharma L*, Li K*. A controlled random gene perturbation method identifies ARPC1B gene as a key regulator of cancer metastasis. Genes Dis. 2022 Jul 7;10(3):687-689.
(7 )Yao Y#, Ye F#, Li K#, Xu P, Tan W, Feng Q*, Rao S#*. Genome and epigenome editing identify CCR9 and SLC6A20 as target genes at the 3p21.31 locus associated with severe COVID-19. Signal Transduct Target Ther. 2021 Feb 22;6(1):85.
(8 )Li K#, Zhang Y#, Liu X#, Liu Y#, Gu Z, Cao H, Dickerson KE, Chen M, Chen W, Shao Z, Ni M, Xu J*. Noncoding Variants Connect Enhancer Dysregulation with Nuclear Receptor Signaling in Hematopoietic Malignancies. Cancer Discov. 2020 May;10(5):724-745.
(9 )Li K#, Liu Y#, Cao H, Zhang Y, Gu Z, Liu X, Yu A, Kaphle P, Dickerson KE, Ni M, Xu J*. Interrogation of enhancer function by enhancer-targeting CRISPR epigenetic editing. Nat Commun. 2020 Jan 24;11(1):485. doi: 10.1038/s41467-020-14362-5.
(10 )Huang J#, Li K#, Cai W, Liu X, Zhang Y, Orkin SH, Xu J*, Yuan GC*. Dissecting super-enhancer hierarchy based on chromatin interactions. Nat Commun. 2018 Mar 5;9(1):943.
4. 联系方式:
李开龙
北京市海淀区学院路38号
北京大学基础医学院生物化学与分子生物学系
Email: kailongli@bjmu.edu.cn